Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alpine Immune Sciences, Inc.

< Previous 1 2 Next >
Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data at the 2023 American Academy of Dermatology Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Participate in the SVB Securities Global Biopharma Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Participation in Fireside Chat at the 5th Annual Evercore ISI HealthCONx Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Report Third Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data at the American Society of Nephrology Kidney Week 2022 Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Pricing of $100 Million Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Proposed Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D. Under Nasdaq Listing Rule 5635(c)
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Participation in May Investor Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
Alpine Immune Sciences Announces Participation in January Investor Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Tickers ALPN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.